Results 131 to 140 of about 5,123 (202)

Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial. [PDF]

Clin J Am Soc Nephrol, 2020
Hayashi T, Maruyama S, Nangaku M, Narita I, Hirakata H, Tanabe K, Morita S, Tsubakihara Y, Imai E, Akizawa T, PREDICT Investigators.   +10 more
europepmc   +1 more source

Hypoxia-inducible factor prolyl hydroxylase domain inhibitor may maintain hemoglobin synthesis at lower serum ferritin and transferrin saturation levels than darbepoetin alfa. [PDF]

PLoS One, 2021
Ogawa C, Tsuchiya K, Tomosugi N, Maeda K.   +3 more
europepmc   +1 more source

Vascular Access Thrombosis Events in Patients With Dialysis-Dependent CKD Treated With Vadadustat or Darbepoetin Alfa: The INNO₂VATE Trial Program. [PDF]

Kidney Med
Winkelmayer WC, Burke SK, Chertow GM, Eckardt KU, Luo W, Minga T, Sarnak MJ, Roy-Chaudhury P.   +7 more
europepmc   +1 more source

The Cost-Effectiveness of Using Epoetin-Beta Versus Darbepoetin-Alfa for the Treatment of Anemia Among Chronic Hemodialysis Patients. [PDF]

Cureus, 2020
AlKharboush H, Alshehri F, Alatwi I, Al Karni K, Alatawi A, Hamdan AM.   +5 more
europepmc   +1 more source

Innovation and market dynamics in the EPO market [PDF]

In this paper we study the demand and supply of erythropoietin in four Nordic countries, using an econometric model based on discrete choice and a random utility model.
Sorisio, Enrico, Strøm, Steinar
core  

Efficacy of ferric carboxymaltose or darbepoetin alfa for chemotherapy-induced anemia in patients with esophagogastric or pancreaticobiliary cancer: a retrospective comparative study. [PDF]

Ther Adv Med Oncol
Cho M, Park E, Lee YP, Kim H, Park HS, Kim HK, Yang Y, Kwon J, Hyeong Lee K, Han HS.   +9 more
europepmc   +1 more source

Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial. [PDF]

Clin J Am Soc Nephrol, 2020
Akizawa T, Nangaku M, Yonekawa T, Okuda N, Kawamatsu S, Onoue T, Endo Y, Hara K, Cobitz AR.   +8 more
europepmc   +1 more source

Erythropoiesis-stimulating agent responsiveness and hemoglobin variability is associated with fat tissue index in hemodialysis patients with darbepoetin-alfa treatment: a prospective observational cohort study. [PDF]

Kidney Res Clin Pract
Yu H, Oh DJ, Kim DH.
europepmc   +1 more source

Impact of transferrin saturation on cardiovascular events in non-dialysis-dependent chronic kidney disease patients treated with darbepoetin alfa. [PDF]

J Nephrol
Nakai K, Nishino T, Kagimura T, Narita I.   +3 more
europepmc   +1 more source

Advancing Anemia Management in Chronic Kidney Disease: Assessing the Superiority of Darbepoetin Alfa Over Erythropoietin Alpha. [PDF]

Cureus
Khullar D, Muchhala SS, T A.
europepmc   +1 more source